Skip to main content

Table 2 Plasma cytokine portraits of primary and SLE-related AIHA patients (pg/ml)

From: CXCL13, CCL4, and sTNFR as circulating inflammatory cytokine markers in primary and SLE-related autoimmune hemolytic anemia

 

Primary (n = 19)

SLE-related (n = 18)

Health control (n = 10)

IFN-γ

30.93 (19.53-45.66)

36.83 (26.72-69.23)

48.78 (38.10-61.94)

I-309/CCL1

65.26 (38.62-108.86)

123.78 (81.56-192.06)

179.66 (96.27-194.22)

MCP-1/CCL2

557.52 (366.62-709.14)

683.57 (546.29-1070.0)

284.96 (200.73-372.66)

MIP-1α/CCL3

77.23 (64.74-119.83)

114.56 (78.54-162.82)

115.37 (93.05-133.28)

MIP-1β/CCL4

23.73 (12.38-38.30)

18.75 (11.11-33.73)

5.05 (4.02-10.22)

MIP-1δ/CCL15 (×104)

0.88 (0.72-1.16)

0.55 (0.29-1.05)

1.37 (0.56-1.85)

RANTES/CCL5 (×103)

4.12 (2.40-7.38)

5.89 (1.52-16.33)

5.03 (1.94-7.24)

Eotaxin/CCL11

95.41 (64.34-138.11)

118.44 (91.65-166.06)

120.81 (92.81-133.95)

Eotaxin-2/CCL24

623.34 (329.62-810.59)

412.51 (282.29-720.39)

289.56 (206.08-370.20)

MIG/CXCL9 (×103)

2.89 (1.95-5.15)

3.11 (2.02-10.26)

2.36 (1.82-4.12)

BLC/CXCL13

147.90 (104.11-436.02)

203.45 (110.74-290.42)

69.14 (56.24-100.39)

ICAM-1 (×105)

1.34 (0.66-1.99)

0.60 (0.49-0.93)

1.88 (0.95-2.73)

G-CSF

11.29 (4.15-24.12)

16.44 (12.83-22.74)

25.12 (14.47-28.15)

M-CSF

35.48 (19.14-66.10)

82.47 (29.22-181.19) #

122.47 (71.49-150.85)

GM-CSF

36.70 (23.65-48.62)

41.60 (25.59-78.01)

48.22 (39.60-72.10)

IL-1α

7.51 (3.00-26.10)

27.28 (7.85-60.07)#

42.77 (24.27-53.30)

IL-1β

63.98 (40.83-159.84)

133.24 (89.85-223.31)#

203.08 (98.42-223.41)

IL-1ra

202.27 (121.20-368.22)

416.94 (192.30-563.72)

121.82 (89.31-196.76)

IL-2

9.04 (5.14-12.20)

9.81 (6.83-18.59)

11.12 (9.43-13.68)

IL-4

8.98 (6.04-16.53)

25.87 (8.61-67.04)#

29.64 (13.45-35.24)

IL-5

67.17 (46.65-116.94)

104.56 (55.58-155.07)

150.04 (103.54-176.69)

IL-6

52.20 (40.23-76.39)

71.41 (40.80-106.07)

62.45 (52.92-72.92)

IL-6sR (×103)

4.05 (3.49-4.70)

4.31 (3.45-5.17)

4.57 (3.78-4.86)

IL-7

72.16 (44.68-115.49)

85.55 (59.18-147.61)

81.55 (72.15-110.65)

IL-8/CXCL8

8.66 (5.81-26.17)

19.15 (9.23-26.68)

4.84 (3.95-7.21)

IL-10

26.68 (17.98-42.12)

37.50 (19.68-71.93)

15.22 (14.40-26.26)

IL-11

205.97 (61.19-342.55)

324.66 (174.49-546.81)

666.37 (487.65-861.28)

IL-12p40

301.15 (83.39-558.00)

570.79 (234.36-1207.2)

277.58 (151.29-403.68)

IL-12p70

4.96 (2.52-9.90)

16.41 (4.91-27.76)#

17.04 (10.93-22.00)

IL-13

6.82 (4.40-9.99)

10.18 (5.87-14.10)

10.87 (10.53-14.63)

IL-15

149.92 (61.75-478.57)

130.10 (87.61-216.20)

194.64 (169.31-233.75)

IL-16

127.04 (87.19-188.99)

187.65 (105.95-365.92)

168.00 (102.51-214.64)

IL-17

89.62 (36.65-197.82)

184.42 (78.67-298.60)

438.99 (279.09-667.12)

TIMP-1 (×104)

1.15 (0.87-1.46)

1.63 (0.77-3.29)

2.18 (1.13-3.67)

TIMP-2 (×104)

1.62 (1.37-1.78)

1.97 (1.40-2.56)

1.97 (1.66-2.26)

PDGF-BB (×103)

2.45 (1.79-2.83)

2.39 (1.99-3.00)

1.56 (1.44-2.00)

TNFα

57.42 (31.45-106.25)

85.66 (36.50-121.91)

104.09 (87.59-148.24)

TNFβ

28.24 (26.75-71.80)

46.24 (27.84-128.56)

92.78 (64.99-144.54)

sTNFRI (×103)

3.41 (2.63-3.68)

4.43 (2.67-5.18)

1.21 (0.89-1.72)

sTNFRII (×103)

3.30 (2.12-4.99)

6.99 (3.84-11.24)※#

2.05 (1.37-2.70)

  1. Data are presented as median (interquartile range). The level of significance for pairwise comparisons was adjusted when multiple comparisons were performed (p = 0.05 / 3 = 0.017).
  2. p <0.017 compared to health control; #p <0.017 compared to primary AIHA.